Author

Joanne Stevens

Institution: Jazz Pharmaceuticals (United States)

Observed institution: Jazz Pharmaceuticals (United States)

ORCID: 0000-0002-0875-577X

Observed ORCID: 0000-0002-0875-577X

OpenAlex ID: A5058503652

Impairment in Functioning and Quality of Life in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)

2023 · Joanne Stevens, Logan D Schneider, et al. · Nature and Science of Sleep · 36

Symptom Severity and Treatment Satisfaction in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)

2023 · Logan Douglas Schneider, Joanne Stevens, et al. · Nature and Science of Sleep · 26

Protocol for EpiCom: A phase 3b/4 study of behavioral outcomes following adjunctive cannabidiol for the management of tuberous sclerosis complex-associated neuropsychiatric disorders (TAND)

2025 · Agnies M. van Eeghen, Elizabeth A. Thiele, et al. · PLoS ONE · 3

Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial (S5.005)

2026 · Agnies van Eeghen, Sarah M.L. Wilson, et al. · Neurology · 1

Behavioral outcomes of treatment with cannabidiol oral solution in individuals with seizures associated with tuberous sclerosis complex: Design of an ongoing phase 4 trial (EPICOM)

2023 · Agnies Van Eeghen, Elizabeth Thiele, et al. · Journal of the Neurological Sciences · 1

Co-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry Together

2026 · Lisa Moore-Ramdin, Agnies van Eeghen, et al. · Patient

Real-world insights into idiopathic hypersomnia symptoms, treatments, and quality of life from the ARISE study: a Plain Language Summary of Publication

2025 · Logan D. Schneider, Amy Desmarais, et al. · Future Neurology

Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorder (TAND) Outcomes Following Add-on Cannabidiol (CBD) Treatment: 3-Month Analysis of Open-Label Phase 3b/4 Trial EpiCom (P8-9.005)

2025 · Agnies van Eeghen, Sarah Wilson, et al. · Neurology

Impairment in Functioning and Quality of Life in Patients With Idiopathic Hypersomnia: the Real World Idiopathic Hypersomnia Outcomes Study (S1.007)

2022 · Logan Schneider, Joanne Stevens, et al. · Neurology

Works count: 9

Citation count: 67

H-index: 3

I10-index: 2